ATE448306T1 - Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung - Google Patents

Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung

Info

Publication number
ATE448306T1
ATE448306T1 AT01966492T AT01966492T ATE448306T1 AT E448306 T1 ATE448306 T1 AT E448306T1 AT 01966492 T AT01966492 T AT 01966492T AT 01966492 T AT01966492 T AT 01966492T AT E448306 T1 ATE448306 T1 AT E448306T1
Authority
AT
Austria
Prior art keywords
conformation
protein
production
desired conformation
stabilized
Prior art date
Application number
AT01966492T
Other languages
English (en)
Inventor
Timothy Springer
Motomu Shimoaka
Chafen Lu
Original Assignee
Blood Res Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blood Res Center filed Critical Blood Res Center
Application granted granted Critical
Publication of ATE448306T1 publication Critical patent/ATE448306T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
AT01966492T 2000-09-01 2001-08-31 Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung ATE448306T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22970000P 2000-09-01 2000-09-01
PCT/US2001/027227 WO2002018583A2 (en) 2000-09-01 2001-08-31 Modified polypeptides stabilized in a desired conformation and methods for producing same

Publications (1)

Publication Number Publication Date
ATE448306T1 true ATE448306T1 (de) 2009-11-15

Family

ID=22862353

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01966492T ATE448306T1 (de) 2000-09-01 2001-08-31 Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung

Country Status (8)

Country Link
US (6) US7160541B2 (de)
EP (1) EP1315812B1 (de)
JP (1) JP5113314B2 (de)
AT (1) ATE448306T1 (de)
AU (1) AU2001287000A1 (de)
CA (1) CA2417432C (de)
DE (1) DE60140457D1 (de)
WO (1) WO2002018583A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5054385B2 (ja) * 2004-02-19 2012-10-24 ダイアックス、コープ 立体配座特異的抗体
US7240492B2 (en) * 2004-07-22 2007-07-10 Sprint Communications Company L.P. Fuel system used for cooling purposes
US7081687B2 (en) * 2004-07-22 2006-07-25 Sprint Communications Company L.P. Power system for a telecommunications facility
CA2576925C (en) * 2004-08-16 2013-12-10 The Cbr Institute For Biomedical Research, Inc. Method of delivering rna interference and uses thereof
US20070018182A1 (en) * 2005-07-20 2007-01-25 Goldeneye, Inc. Light emitting diodes with improved light extraction and reflectivity
WO2007048186A1 (en) * 2005-10-25 2007-05-03 Baker Medical Research Institute Leukocyte-binding polypeptides and uses thereof
WO2007070488A2 (en) * 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
EP2020992A2 (de) * 2006-04-24 2009-02-11 The CBR Institute for Biomedical Research, Inc. Verfahren zur herstellung von immunliposomen und zusammensetzungen daraus
US20100008937A1 (en) * 2006-04-25 2010-01-14 Immune Disease Institute, Inc. Targeted delivery to leukocytes using non-protein carriers
CN101490548A (zh) * 2006-06-02 2009-07-22 哈佛大学校长及研究员协会 蛋白质表面重建
AU2007256780B2 (en) 2006-06-02 2013-08-29 President And Fellows Of Harvard College Protein surface remodeling
WO2008006087A2 (en) * 2006-07-07 2008-01-10 The Regents Of The University Of California Antibodies to conformationally trapped proteins
EP2297182A4 (de) * 2008-04-28 2012-08-15 Harvard College Supergeladene proteine zur zellpenetration
US8877893B2 (en) * 2008-12-29 2014-11-04 Children's Medical Center Corporation Stabilized low affinity conformation of integrins for drug discovery
US9221886B2 (en) 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration
ES2997080T3 (en) * 2010-10-25 2025-02-14 Biogen Ma Inc Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
EP2694109A4 (de) * 2011-04-07 2015-02-18 Neotope Biosciences Ltd Zusammensetzungen und verfahren zur behandlung von proteinaggregationskrankheiten mit ic3b-abscheidung
EP2701699B1 (de) 2011-04-28 2019-10-16 The Broad Institute, Inc. Histondeacetylase-hemmer
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
WO2014124020A1 (en) 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner
US12128018B2 (en) 2018-01-12 2024-10-29 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer
US12291562B2 (en) 2019-04-01 2025-05-06 Rush University Medical Center Reagents and assays using modified integrin domains
US11100297B2 (en) * 2019-04-15 2021-08-24 International Business Machines Corporation Provision of natural language response to business process query

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
JPH01502879A (ja) 1987-02-26 1989-10-05 ダナ　ファーバー　キャンサー　インスティテュート Ｌｆａ―１のクローニング
US5565550A (en) 1987-05-04 1996-10-15 Dana Farber Cancer Institute Antibodies to ICAM-2, and fragments thereof
US5512660A (en) 1987-05-04 1996-04-30 Dana Farber Cancer Institute, Inc. Purified ICAM-2 and fragment thereof
US5831036A (en) 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5489533A (en) 1987-05-04 1996-02-06 Dana Farber Cancer Institute Isolated nucleic acid molecules encoding ICAM-2
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5395929A (en) 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
EP0364690A3 (de) 1988-08-23 1990-07-18 Dana Farber Cancer Institute Alpha-Subeinheit des Mac-1-Leukocyt-Adhäsions-Rezeptors
EP1541682A3 (de) 1988-09-02 2005-07-06 Dyax Corp. Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6511664B1 (en) 1989-03-09 2003-01-28 Dana Farber Cancer Institute Intercellular adhesion molecule—2 and its binding ligands
US6797270B1 (en) 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
US6777191B1 (en) 1989-03-16 2004-08-17 Center For Blood Research, Inc. Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in diagnosis of viral infection
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0950707B1 (de) 1989-07-25 2009-02-18 Cell Genesys, Inc. Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
NZ236792A (en) 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
IL98764A0 (en) 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5288854A (en) 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
US5460945A (en) 1991-05-30 1995-10-24 Center For Blood Research, Inc. Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response
US5891841A (en) 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
EP0940468A1 (de) 1991-06-14 1999-09-08 Genentech, Inc. Änderliches Gebiet einer humanisierter Antikörper
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
DK0656789T3 (da) * 1992-08-21 1998-08-24 Genentech Inc Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
US5877295A (en) 1992-09-30 1999-03-02 The Center For Blood Research Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5470953A (en) 1993-12-23 1995-11-28 Icos Corporation Human β2 integrin α subunit
GB2298520B (en) * 1995-03-03 1999-09-08 Hong Chen Fu In Heat sink device for integrated circuit
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888765A (en) 1995-06-23 1999-03-30 President And Fellows Of Harvard College Endothelial-cell specific promoter
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5914112A (en) 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US5843712A (en) * 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
DK0941344T3 (da) * 1996-11-27 2004-09-27 Genentech Inc Humaniserede anti-CD11a-antistoffer
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
PT998486E (pt) 1997-06-13 2007-08-21 Genentech Inc ''recuperação de proteínas por cromatografia seguida de filtração numa camada carregada''
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6582698B1 (en) * 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
SG83788A1 (en) 1999-04-13 2001-10-16 Mitsui Chemicals Inc Method for preparing polymer
EP1237575B1 (de) 1999-12-14 2008-08-06 Genentech, Inc. Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
JP3933847B2 (ja) 2000-06-19 2007-06-20 ユニ・チャーム株式会社 吸収性物品
US6951927B2 (en) 2000-07-07 2005-10-04 California Institute Of Technology Proteins with integrin-like activity

Also Published As

Publication number Publication date
US20020123614A1 (en) 2002-09-05
WO2002018583A2 (en) 2002-03-07
JP2004527217A (ja) 2004-09-09
AU2001287000A1 (en) 2002-03-13
US7879577B2 (en) 2011-02-01
DE60140457D1 (de) 2009-12-24
EP1315812A2 (de) 2003-06-04
JP5113314B2 (ja) 2013-01-09
US8241627B2 (en) 2012-08-14
US20050182244A1 (en) 2005-08-18
US7674604B2 (en) 2010-03-09
US7968284B2 (en) 2011-06-28
US20110111528A1 (en) 2011-05-12
WO2002018583A3 (en) 2003-01-30
CA2417432A1 (en) 2002-03-07
US7241869B2 (en) 2007-07-10
US20110305691A1 (en) 2011-12-15
US20100113742A1 (en) 2010-05-06
WO2002018583A9 (en) 2003-10-30
EP1315812B1 (de) 2009-11-11
US20050260192A1 (en) 2005-11-24
US7160541B2 (en) 2007-01-09
CA2417432C (en) 2010-11-02

Similar Documents

Publication Publication Date Title
DE60140457D1 (de) Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
Koivunen et al. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins
BRPI0516011A (pt) moléculas fc modificadas
Haskell-Luevano et al. Compounds that activate the mouse melanocortin-1 receptor identified by screening a small molecule library based upon the β-turn
BRPI0412007A (pt) mutagênese look-through
CY1108691T1 (el) Πολυπεπτιδια
NO20025354L (no) Pattedyr-reseptorproteiner; beslektede reagenser og fremgangsmåter
KR960022562A (ko) 항-αV-인터그린 모노크로날 항체
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
HUP0302395A2 (hu) Eljárás kémiai úton előállított polipeptidek hajtogatott térszerkezetének kialakítására
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
ES2085993T3 (es) Proteina asociada a la pancreatitis aguda, medios para el diagnostico de la pancreatitis aguda.
EP0628054A4 (de) Car-rezeptoren und verwandte moleküle und entsprechende methoden.
DE69942668D1 (de) Humanisierter monoklonaler antikörper gegen von-willebrand faktor
DE60129239D1 (de) Kit und verfahren zur bestimmung von protein esm-1
FI953525L (fi) Kemiallinen syntetointimenetelmä fibronektiiniä sitovan proteiinin tai polypeptidin valmistamiseksi
ATE234918T1 (de) Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
DE60034117D1 (de) Verfahren zur herstelllung von gonadotropin-zusammensetzungen
Rentier et al. The 3‐nitro‐2‐pyridinesulfenyl group: synthesis and applications to peptide chemistry
DE69535831D1 (de) Hemopoietin-rezeptor
DE69840895D1 (de) Monospezifische antikörper gegen fibrinogen und fibrinopeptide b
Zhang et al. Synthesis, Biological Activity, and Conformational Analysis of Peptidomimetic Analogues of the Saccharomyces c erevisiae α-Factor Tridecapeptide
Zhang et al. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications
DE69835047D1 (de) Schaumproteine, monoklonale Antikörper dagegen, und deren Verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties